Trial reportCirculation2015
Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects.
5 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03532620. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension
PMID 24793439PMID 27039945PMID 22878405PMID 21028996PMID 19104004PMID 20736443PMID 18997196PMID 12551878other papers from this trial
Open the trial in the graphComparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial
PMID 21812889PMID 24998014PMID 25575403PMID 26084792PMID 22878405PMID 18981652PMID 23352266PMID 21028996PMID 27181110PMID 25109606PMID 25312577PMID 21693744other papers from this trial
Open the trial in the graphEffect of Statin Use on Aldosterone Secretion
Hypertension and Striatin Gene Structure Related to Aldo Phenotype
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Sex Differences in Coronary Microvascular Function in Individuals With Type 2 Diabetes.Diabetes · 2019Trial
- The impact of statins on aldosterone production in healthy adults: a randomized controlled study.Journal of the Endocrine Society · 2026Article
- Very low-density lipoprotein and the human health.World journal of experimental medicine · 2026Review
- Class A scavenger receptor MARCO negatively regulates Ace expression and aldosterone production.eLife · 2025Article
- Lipid metabolism in the adrenal gland.Frontiers in endocrinology · 2025Review
- Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes.Physiological reports · 2024Article
- The role of aldosterone and ideal cardiovascular health in incident cardiovascular disease: The Jackson heart study.American journal of preventive cardiology · 2023Article
- Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II.International journal of molecular sciences · 2023Article
- Statin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting.Frontiers in endocrinology · 2023Article
- Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).International journal of molecular sciences · 2022Review
- Associations of trauma and posttraumatic stress disorder with aldosterone in women.Psychoneuroendocrinology · 2021Article
- Effects of Statins on Renin-Angiotensin System.Journal of cardiovascular development and disease · 2021Review
- The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study.Journal of clinical medicine · 2021Article
- Acute Statin Administration Reduces Levels of Steroid Hormone Precursors.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020Article
- Repurposing existing drugs for COVID-19: an endocrinology perspective.BMC endocrine disorders · 2020Article
- Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone.Hypertension (Dallas, Tex. : 1979) · 2020 · on this mapObservational
- Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.The Journal of clinical endocrinology and metabolism · 2020Observational
- A clinical trial to evaluate the effect of statin use on lowering aldosterone levels.BMC endocrine disorders · 2020Article
- The Association of Life's Simple 7 with Aldosterone among African Americans in the Jackson Heart Study.Nutrients · 2019Article
- Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress.Life sciences · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Rene BaudrandFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.). rbaudran@uc.cl gwilliams@partners.org.
Luminita H PojogaFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Anand VaidyaFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Amanda E GarzaFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Paul A VöhringerFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Xavier JeunemaitreFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Paul N HopkinsFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Tham M YaoFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Jonathan WilliamsFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Gail K AdlerFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.).
Gordon H WilliamsFrom Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.B., L.H.P., A.V., A.E.G., T.M.Y., J.W., G.K.A., G.H.W.); Department of Endocrinology, School Of Medicine, Pontificia Universidad Catolica De Chile, Santiago, Chile (R.B.); Hospital Clinico, Facultad Medicina Universidad de Chile, Santiago, Chile and Tufts Medical Center, Tufts University School of Medicine, Boston, MA (P.A.V.); Centre Investigation Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Universite Paris Descartes, Paris, France (X.J.); and Cardiovascular Genetics Research, University of Utah School of Medicine Salt Lake City (P.N.H.). rbaudran@uc.cl gwilliams@partners.org.
Tufts Medical Center · USUniversity of Chile · CLTufts University · USPontificia Universidad Católica de Chile · CL
Funding
SCOR MOLECULAR GENETICS OF HYPERTENSIONP50HL055000 · BRIGHAM AND WOMEN'S HOSPITAL · 1996 to 2005
$13.5MTRAINING PROGRAM IN HYPERTENSIONT32HL007609 · BRIGHAM AND WOMEN'S HOSPITAL · 1985 to 2005
$2.4MMechanisms of Aldosterone Induced Cardiovascular DamageR01HL069208 · BRIGHAM AND WOMEN'S HOSPITAL · 2003 to 2005
$1.4MSalt Sensitive Hypertension and StriatinR01HL144779 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GORDON H WILLIAMS · 2022 to 2022
$834kNCATS NIH HHS UL1 TR001102NHLBI NIH HHS HL104032NHLBI NIH HHS HL-69208NHLBI NIH HHS K23 HL111771NHLBI NIH HHS K23HL111771NHLBI NIH HHS K24 HL103845NHLBI NIH HHS L30 HL104553NHLBI NIH HHS P50 HL055000NHLBI NIH HHS R01 HL069208NHLBI NIH HHS R01 HL086907NHLBI NIH HHS R01 HL087060NHLBI NIH HHS R01 HL087060-01NHLBI NIH HHS R01 HL104032NHLBI NIH HHS R01HL11476NHLBI NIH HHS R01 HL114765NHLBI NIH HHS R01 HL144779NHLBI NIH HHS T32 HL007609NHLBI NIH HHS T32HL007609NIDDK NIH HHS R01 DK107407
Abstract
backgroundStatins substantially reduce cardiovascular mortality and appear to have beneficial effects independent of their lipid-lowering properties. We evaluated the hypothesis that statin use may modulate the secretion of aldosterone, a well-known contributor to cardiovascular disease. METHODS AND
resultsWe measured adrenal hormones in 2 intervention studies. In study 1 in hypertensive subjects, aldosterone was analyzed at baseline and after angiotensin II stimulation on both high- and low-sodium diets (1122 observations, 15% on statins for >3 months). Statin users had 33% lower aldosterone levels in adjusted models (P<0.001). Cortisol was not modified by statins. In secondary analyses, the lowest aldosterone levels were seen with lipophilic statins and with higher doses. Statin users had lower blood pressure and reduced salt sensitivity of blood pressure (both P<0.001). In study 2, aldosterone was measured in diabetic patients on a high-sodium diet, before and after angiotensin II stimulation (143 observations, 79% statin users). Again, statin users had 26% lower aldosterone levels (P=0.006), particularly those using lipophilic statins. Ex vivo studies in rat adrenal glomerulosa cells confirmed that lipophilic statins acutely inhibited aldosterone, but not corticosterone, in response to different secretagogues.
conclusionsStatin use among hypertensive and diabetic subjects was associated with lower aldosterone secretion in response to angiotensin II and a low-sodium diet in 2 human intervention studies. This effect appeared to be most pronounced with lipophilic statins and higher doses. Future studies to evaluate whether aldosterone inhibition may partially explain the robust cardioprotective effects of statins are warranted.
Indexed as
Adrenal GlandsAdultAldosteroneAnimalsDiabetes MellitusDiet, Sodium-RestrictedFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMaleMiddle AgedRatsRats, WistarAldosteroneHydroxymethylglutaryl-CoA Reductase Inhibitorsadrenal cortex hormonesaldosteroneglucocorticoidshypertensionsodiumstatin
Identifiers
What Socratic holds
Texttitle and abstract
LicenceTDM
Read underepoch 390
Registered trials
NCT03532620ClinicalTrials.gov
NCT04945122ClinicalTrials.gov
NCT02871687ClinicalTrials.gov
NCT03683069ClinicalTrials.gov
NCT05593055ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.